Healthcare
Orexo AB (publ)(ORXOF)
Live Price
Offline$2.10
+0.00% today
1Y Change
+94.44%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $660.00M
- Revenue Growth
- -95.6%
- EPS Growth
- +36.5%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Orexo AB (publ) (ORXOF) is a Healthcare stock with a market cap of $660.00M and listed on OTC. The stock last traded around $2.10 and up 94.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -95.6%, EPS growth of +36.5%, a dividend yield of 0.0%. What stands out right now is revenue -95.6%, EPS +36.5%, free cash flow +563.9% with operating margin -91.1% and ROIC -58.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ORXOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-95.6% vs +7.6% peer median
Operating Margin
Below sector median
-91.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -95.6% and EPS is at +36.5%, with operating margin around -91.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 5, 2026 | -323.3% | +0.0% | +0.0% | +0.0% |
2025 Oct 23, 2025 | -80.0% | +0.0% | +5.2% | +5.2% |
Benchmark Edge
ORXOF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORXOF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORXOF Max Drawdown
-34.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORXOF and SPY.
Company Overview
Orexo AB (publ)
Other OTC
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
- Leadership
- Nikolaj Sorensen
- IPO Date
- Apr 11, 2013
- Employees
- 110
- Street Address
- P.O. Box 303
- Mailing
- Uppsala, 751 05
- Region
- Uppsala, SE
- Reporting Currency
- USD
- Investor Line
- 46 1 87 80 88 00
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.7
- Price/Book
- 1.8
Growth
- Revenue
- -95.6%
- EPS
- +36.5%
- Free Cash Flow
- +563.9%
Profitability
- Gross Margin
- -71.9%
- Operating Margin
- -91.1%
- Net Margin
- -101.1%
- ROE
- -228.4%
- ROIC
- -58.9%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 2.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.